1xbet 신청., Ltd.

Otsuka Pharmaceutical Co., Ltd. announces that it has received regulatory approval in Japan 1xbet 신청 additional indication of suppression of recurrence and relapse of mood episodes in bipolar I disorder for ABILIFY MAINTENA (aripiprazole), a long-acting injectable suspension. The approved indication covers the 300 mg and 400 mg vials (for injection) and the 300 mg and 400 mg dual-chamber syringes.

ABILIFY MAINTENA is a depot preparation 1xbet 신청 intramuscular injection that administered monthly as a single injection.

Otsuka Pharmaceutical discovered ABILFY MAINTENA, an atypical antipsychotic, which first received regulatory approval in 2013 in the U.S. and E.U. 1xbet 신청 treatment of adult schizophrenia. In 2015, it was approved in Japan 1xbet 신청 same indication. In the U.S. and Canada, the indication as maintenance therapy for adult bipolar I maintenance therapy was added in 2017.